- Home
- MRLN vs SPRY Comparison
MRLN vs SPRY Comparison
Compare MRLN & SPRY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | MRLN | SPRY |
|---|---|---|
| Founded | 2018 | 2015 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | EDP Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 915.1M | 823.2M |
| IPO Year | 2024 | 2020 |
Fundamental Metrics
Financial Performance| Metric | MRLN | SPRY |
|---|---|---|
| Price | $6.73 | $7.77 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 1 | 1 |
| Target Price | $25.00 | ★ $40.00 |
| AVG Volume (30 Days) | 1.3M | ★ 1.8M |
| Earning Date | 10-28-2021 | 05-11-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $84,278,000.00 |
| Revenue This Year | N/A | $87.40 |
| Revenue Next Year | N/A | $81.64 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $5.88 | $6.66 |
| 52 Week High | $17.00 | $18.63 |
Technical Indicators
Market Signals| Indicator | MRLN | SPRY |
|---|---|---|
| Relative Strength Index (RSI) | 39.46 | 44.65 |
| Support Level | $6.22 | $6.93 |
| Resistance Level | $17.00 | $8.61 |
| Average True Range (ATR) | 1.00 | 0.54 |
| MACD | -0.30 | -0.13 |
| Stochastic Oscillator | 19.22 | 30.51 |
Price Performance
Historical ComparisonAbout MRLN Merlin Inc. Common Stock
Merlin Inc is focused on developing autonomous flight software for legacy and next-generation airborne systems. Its aircraft-agnostic, AI-based software supports takeoff-to-landing autonomous operations for military and civil aviation programs. The company aims to build an AI-based operating software platform intended to support autonomous flight operations across a range of aircraft types.
About SPRY ARS Pharmaceuticals Inc.
ARS Pharmaceuticals Inc is a biopharmaceutical company focused on the commercialization and development of neffy (currently identified in the European Union (EU) and United Kingdom (U.K.) by the trade name EURneffy and in China) for needle-free intranasal delivery of epinephrine for emergency treatment of Type I allergic reactions, including anaphylaxis. Neffy is a proprietary composition of epinephrine with an absorption enhancer called Intravail, which allows Neffy to safely provide intranasal delivery of epinephrine at a low dose within the exposures of approved injectable products across a range of dosing conditions.